Nexlizet, a two-in-one cholesterol tablet, is now registered in Australia

Nov 2026
Pharmacist handing a prescription bag to a patient, illustrating Nexlizet’s approval in Australia
Nexlizet is now registered in Australia, but it isn’t automatically PBS-subsidised. Ask your doctor or pharmacist whether it’s right for you.

What’s changed

The Therapeutic Goods Administration (TGA) has approved Nexlizet, a single tablet combining two established cholesterol-lowering medicines: 180 mg of bempedoic acid and 10 mg of ezetimibe. The TGA made its decision on 17 September 2026, and the medicine was entered on the Australian Register of Therapeutic Goods a week later, on 24 September. The sponsor is Seqirus Pty Ltd (CSL Seqirus).

Who it’s for

Nexlizet is approved for adults with primary hypercholesterolaemia (high blood cholesterol, whether inherited or not) or mixed dyslipidaemia (unhealthy levels of more than one type of blood fat, such as cholesterol and triglycerides). It is also approved for adults who have atherosclerotic cardiovascular disease, or who are at high risk of developing it.

When it can be used

Nexlizet isn’t a first-line treatment. It’s taken alongside lifestyle changes, or alongside measures to manage other cardiovascular risk factors, in three situations:

  • with a statin, when the highest statin dose a person can tolerate, together with ezetimibe, hasn’t lowered LDL (“bad”) cholesterol enough
  • without a statin, when someone can’t tolerate one or shouldn’t take one for other medical reasons, and ezetimibe alone hasn’t brought their LDL cholesterol down far enough
  • in place of separate bempedoic acid and ezetimibe tablets, with or without a statin

For people already taking both medicines, that last point means one tablet a day instead of two.

How it works

The two ingredients tackle cholesterol from different directions. Bempedoic acid blocks an enzyme the liver uses to make cholesterol, while ezetimibe reduces how much cholesterol is absorbed from the gut. With less cholesterol available, the liver pulls more LDL out of the bloodstream.

The evidence behind it

The TGA’s assessment rested mainly on one trial of 301 people, all of whom stayed on the highest statin dose they could tolerate. After 12 weeks, the combination tablet had lowered LDL cholesterol more than bempedoic acid alone, ezetimibe alone or a placebo. In other words, the two ingredients do more together than either does on its own.

Nexlizet itself hasn’t been tested in a dedicated trial measuring heart attacks, strokes or cardiovascular deaths. A separate trial of bempedoic acid did include people who were also taking ezetimibe, and that group showed a trend towards better cardiovascular outcomes. The TGA also pointed to wider evidence that the two medicines improve outcomes when taken separately.

Safety

Nexlizet’s safety profile was similar to that already known for its two ingredients, and the TGA found no new safety concerns. Full details of side effects and precautions are in the Consumer Medicine Information leaflet and the Product Information.

Worth knowing

Registration means Nexlizet can legally be supplied in Australia. It doesn’t automatically mean it’s subsidised under the PBS, so check the PBS website for current listing and eligibility. The TGA’s more detailed assessment report (AusPAR) is due to follow.

Read more: Ingham CT Scanner Now Live, Delivering 2,500 Essential Scans a Year


General information only, not legal advice. Check the official source before acting.

Source: Therapeutic Goods Administration.

Scroll to Top